RESULTS: Ten women were enrolled in the study. The mean fat graft volume per breast augmentation was 310 ml fat (range, 300-350 ml). The cell enrichment of the fat grafts did not improve the volume retention after 4 months or 1 year. After 4 months, the retention of the cell-enriched grafts was 54.3% (95% confidence interval [CI], 39.4-69.2) versus 56.2% (95% CI, 42.7-69.6) in the control group (P = 0.552). After 12 months, the retention in the cell-enriched grafts was 54.0% (95% CI, 30.4-77.6) versus 55.9% (95% CI, 28.9-82.9) in the control group (P = 0.566). The difference in mean retention after 1 year was only −1.9 % (95% CI, −9.11% to 5.31%). No serious adverse events occurred in any of the patients.
RESULTS: Ten women were enrolled in the study. The mean fat graft volume per breast augmentation was 310 ml fat (range, 300-350 ml) . The cell enrichment of the fat grafts did not improve the volume retention after 4 months or 1 year. After 4 months, the retention of the cell-enriched grafts was 54.3% (95% confidence interval [CI] , 39.4-69.2) versus 56.2% (95% CI, 42.7-69.6) in the control group (P = 0.552). After 12 months, the retention in the cell-enriched grafts was 54.0% (95% CI, 30.4-77.6) versus 55.9% (95% CI, 28.9-82.9) in the control group (P = 0.566). The difference in mean retention after 1 year was only −1.9 % (95% CI, −9.11% to 5.31%). No serious adverse events occurred in any of the patients.
CONCLUSION:
Our study showed that enriching fat grafts with high-dose expanded adipose-derived stromal cells did not lead to any improvement in fat graft survival in the breast. 
Breast Flap Neurotization Following Autologous Breast Reconstruction: A Prospective Trial
Presenter: Shelby Nathan, MD
Co-Authors: Jaclyn Mauch, BS; Cutler Whitely, BS; Michael G. Tecce, DO; Irfan A. Rhemtulla, MD, MS; Geoffrey Kozak, MD; Joseph M. Serletti, MD
Affiliation: University of Pennsylvania, Philadelphia, PA PURPOSE: Restoration of breast sensation following autologous breast reconstruction (ABR) is integral to the reconstructive paradigm for breast cancer patients. We hypothesize that innervation of reconstructed breast flaps will improve sensation and quality of life (QoL).
MATERIALS/METHODS:
Free flap ABR patients with and without nerve allograft neurotization were recruited prospectively. Sensation testing was performed with a Pressure Specified Sensory Device (PSSD) at 12-24 months postoperatively in superior, lateral, medial, and inferior poles on both the mastectomy skin and the flap skin. The BREAST-Q was administered.
RESULTS:
Thirty-two women were enrolled with a total of 54 reconstructed breasts (neurotized: n = 22; nonneurotized: n = 32). Average age was 51.9 years (range, 21-77) with a mean body mass index of 28.9 (range, 20-47). Average follow-up was 15.8 months (range, 12-24). Free TRAM flaps were most commonly performed (87%). Mastectomy skin exhibited greater sensation than flap skin (P = 0.20) and 1-point moving tests elicited a greater response than 1-point static (P < 0.00). In all but one area (inferior mastectomy), the neurotized group had more sensation with 1-point static (P = 0.01-0.99) and 1-point moving testing (P = 0.33-0.92). The superior mastectomy pole experienced significantly greater sensation in the neurotized group (P < 0.001). There was no difference in surgical site outcomes between the groups. Nine percentage neurotized versus 5% nonneurotized patients reported "more sensation" after reconstruction (P = 0.32). QoL demonstrated that the neurotized group was more satisfied in 9 of the 11 parameters (P = 0.09-0.89).
CONCLUSION:
The return of breast sensation after ABR has become an important topic in reconstructive plastic surgery. Although multiple modalities have been proposed to increase postoperative sensation (eg, nerve conduits, allografts, and autografts), there is a paucity of prospective clinical trials investigating sensory outcomes. This abstract highlights the largest cohort to date, which quantitatively and qualitatively measures the effect of neurotization with nerve allografts on the return of sensation following ABR.
To do so, we have directly measured sensation, patientreported return of sensation, and breast-associated QoL. These preliminary results suggest that neurotization during ABR may lead to increased sensation and improved QoL. We hope that these results will further the knowledge of this topic, potentially improve patient outcomes, and stimulate a discussion regarding clinical management.
